Nonalcoholic Steatohepatitis (NASH)

Infectious Diseases
13
Pipeline Programs
7
Companies
14
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
1
7
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 10 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
5 programs
3
2
FirsocostatPhase 2Small Molecule1 trial
SELPhase 21 trial
CilofexorPhase 1
CilofexorPhase 12 trials
FirsocostatPhase 1Small Molecule1 trial
Active Trials
NCT04060147Terminated11Est. Sep 2021
NCT02808312Completed57Est. Oct 2018
NCT02891408Completed74Est. May 2019
+2 more trials
Corcept Therapeutics
Corcept TherapeuticsCA - Redwood City
4 programs
2
2
MiricorilantPhase 21 trial
MiricorilantPhase 21 trial
MiricorilantPhase 11 trial
Miricorilant 150 mgPhase 11 trial
Active Trials
NCT06947304Recruiting8Est. May 2026
NCT05117489Completed70Est. Jan 2024
NCT06108219Active Not Recruiting175Est. Sep 2026
+1 more trials
Bristol Myers Squibb
1 program
1
BMS-986263Phase 22 trials
Active Trials
NCT04267393Terminated124Est. Feb 2024
NCT04225936Completed40Est. Jun 2021
GSK
GSKLONDON, United Kingdom
1 program
1
EfimosferminPhase 21 trial
Active Trials
NCT04880031Completed231Est. Oct 2025
Hepion Pharmaceuticals
1 program
1
RencofilstatPhase 2Small Molecule1 trial
Active Trials
NCT05402371Active Not Recruiting120Est. Sep 2025
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
FT-4101Phase 1/21 trial
Active Trials
NCT04004325Terminated14Est. Jan 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Corcept TherapeuticsMiricorilant
Hepion PharmaceuticalsRencofilstat
GSKEfimosfermin
Bristol Myers SquibbBMS-986263
Corcept TherapeuticsMiricorilant
Gilead SciencesFirsocostat
Gilead SciencesSEL
Novo NordiskFT-4101
Corcept TherapeuticsMiricorilant
Corcept TherapeuticsMiricorilant 150 mg
Bristol Myers SquibbBMS-986263
Gilead SciencesCilofexor
Gilead SciencesFirsocostat
Gilead SciencesCilofexor

Clinical Trials (14)

Total enrollment: 1,283 patients across 14 trials

NCT06108219Corcept TherapeuticsMiricorilant

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Start: Oct 2023Est. completion: Sep 2026175 patients
Phase 2Active Not Recruiting
NCT05402371Hepion PharmaceuticalsRencofilstat

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

Start: Oct 2022Est. completion: Sep 2025120 patients
Phase 2Active Not Recruiting
NCT04880031GSKEfimosfermin

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

Start: Sep 2021Est. completion: Oct 2025231 patients
Phase 2Completed
NCT04267393Bristol Myers SquibbBMS-986263

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

Start: Mar 2021Est. completion: Feb 2024124 patients
Phase 2Terminated
NCT03823703Corcept TherapeuticsMiricorilant

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Start: Nov 2020Est. completion: Apr 202112 patients
Phase 2Terminated
NCT02856555Gilead SciencesFirsocostat

Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

Start: Aug 2016Est. completion: Jul 2017127 patients
Phase 2Completed
NCT02781584Gilead SciencesSEL

Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)

Start: Jun 2016Est. completion: Dec 2020220 patients
Phase 2Completed
NCT04004325Novo NordiskFT-4101

A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

Start: May 2019Est. completion: Jan 202014 patients
Phase 1/2Terminated
NCT06947304Corcept TherapeuticsMiricorilant

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Start: Aug 2025Est. completion: May 20268 patients
Phase 1Recruiting
NCT05117489Corcept TherapeuticsMiricorilant 150 mg

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Start: Nov 2021Est. completion: Jan 202470 patients
Phase 1Completed
NCT04225936Bristol Myers SquibbBMS-986263

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

Start: Jan 2020Est. completion: Jun 202140 patients
Phase 1Completed
NCT04060147Gilead SciencesCilofexor

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Start: Oct 2019Est. completion: Sep 202111 patients
Phase 1Terminated
NCT02891408Gilead SciencesFirsocostat

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function

Start: Sep 2016Est. completion: May 201974 patients
Phase 1Completed
NCT02808312Gilead SciencesCilofexor

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Start: Jul 2016Est. completion: Oct 201857 patients
Phase 1Completed

Related Jobs in Infectious Diseases

Senior Recruiter

Invivyd
New Haven, CT (Northeast preferred)
5h ago
$120K - $160K/yr

Senior Associate Scientist (contract), Upstream Polysaccharide Process Development

VaxCyte
San Carlos, California, United States
8h ago
$56/hr

Senior Associate Scientist (contract), Polysaccharide Analytical Development

VaxCyte
San Carlos, California, United States
8h ago
$56/hr

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
12h ago
$179K - $237K/yr

First Line Sales Leader (Medan)

GSK
Indonesia - Sumatera Utara
Yesterday

General Worker

GSK
Pakistan - Sindh - Karachi
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,283 patients
7 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)